Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S7SE
|
|||
| Former ID |
DIB018337
|
|||
| Drug Name |
[3H]methoxymethyl-MTEP
|
|||
| Synonyms |
3-(Methoxymethyl)-5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; Pyridine, 3-(methoxymethyl)-5-[(2-methyl-4-thiazolyl)ethynyl]-; CHEMBL1169453; 3-(methoxymethyl)-5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; methoxymethyl-MTEP; 524924-75-2; [3H]-methoxymethyl-MTEP; CHEMBL420533; GTPL5394; GTPL3345; SCHEMBL5652003; CTK1E4453; DTXSID90438611; AWDRAHDWMICWJM-UHFFFAOYSA-N; BDBM50366853; 3-Methoxymethyl-5-(2-methyl-thiazol-4-ylethynyl)-pyridine; 3-(2-Methyl-4-thiazolylethynyl)-5-(methoxymethyl)pyridine; [3H]-methoxymethyl-MTEP
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C13H12N2OS
|
|||
| Canonical SMILES |
CC1=NC(=CS1)C#CC2=CN=CC(=C2)COC
|
|||
| InChI |
1S/C13H12N2OS/c1-10-15-13(9-17-10)4-3-11-5-12(8-16-2)7-14-6-11/h5-7,9H,8H2,1-2H3
|
|||
| InChIKey |
AWDRAHDWMICWJM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 524924-75-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metabotropic glutamate receptor 5 (mGluR5) | Target Info | Modulator (allosteric modulator) | [3], [4] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Long-term potentiation | ||||
| Retrograde endocannabinoid signaling | ||||
| Glutamatergic synapse | ||||
| Huntington's disease | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
| Metabotropic glutamate receptor group III pathway | ||||
| Metabotropic glutamate receptor group I pathway | ||||
| Endogenous cannabinoid signaling | ||||
| Reactome | G alpha (q) signalling events | |||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | Hypothetical Network for Drug Addiction | |||
| GPCRs, Class C Metabotropic glutamate, pheromone | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5394). | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3345). | |||
| REF 3 | [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1044-51. | |||
| REF 4 | [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett. 2003 Feb 10;13(3):351-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.